New CGM device aims to help diabetes patients stay in range
NCT ID NCT06904846
First seen Jan 15, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This study tests a new continuous glucose monitor (iCan O3) in 70 adults with type 1 or type 2 diabetes whose blood sugar is not well controlled. Participants wear the device for 60 days, first with blinded readings and then with real-time data, to see if it helps them spend more time in their target blood sugar range. The goal is to improve daily diabetes management and reduce fingerstick testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UZA ANTWERP UZA Dienst Endocrinologie
Antwerp, Belgium
Conditions
Explore the condition pages connected to this study.